Compare Davita Inc (DVA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Vital Farms Inc — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Vital Farms Inc trades at $13.03 (market cap $561.10M). The key difference: Davita Inc is far larger — about 26.6× Vital Farms Inc's market cap, and Davita Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VITL | |
|---|---|---|
Market Cap | $14.92B | $561.10M |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $52.41 |
52-Week Low | $103.87 | $8.28 |
Enterprise Value | $27.47B | $563.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Vital Farms (VITL) trades at $12.78, down 1.31% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 15.44% ROE and attractive valuation ratios (P/E 12.59, P/S 0.76). Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while revenue grew to $759M in 2025. The stock faces headwinds from multiple class action lawsuits filed in May 2026, creating investor uncertainty despite analyst consensus favoring a buy rating.
The outlook remains cautiously optimistic with a $13.50 consensus price target offering 5.6% upside potential. Key opportunities include sustained profitability and market positioning in natural foods, while risks center on legal challenges and projected earnings volatility. Institutional sentiment leans bullish with no sell ratings, but negative cash flow trends require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
